Amphastar Pharmaceuticals PE Ratio 2012-2026 | AMPH
Current and historical p/e ratio for Amphastar Pharmaceuticals (AMPH) from 2012 to 2026. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Amphastar Pharmaceuticals PE ratio as of September 17, 2026 is 9.58.
| Amphastar Pharmaceuticals PE Ratio Historical Data | |||
|---|---|---|---|
| Date | Stock Price | TTM Net EPS | PE Ratio |
| 2026-09-17 | 23.82 | 14.09 | |
| 2026-06-30 | 20.18 | $1.69 | 11.94 |
| 2026-03-31 | 19.59 | $1.66 | 11.80 |
| 2025-12-31 | 26.78 | $2.03 | 13.19 |
| 2025-09-30 | 26.65 | $2.26 | 11.79 |
| 2025-06-30 | 22.96 | $2.67 | 8.60 |
| 2025-03-31 | 28.99 | $2.76 | 10.50 |
| 2024-12-31 | 37.13 | $3.06 | 12.13 |
| 2024-09-30 | 48.53 | $3.02 | 16.07 |
| 2024-06-30 | 40.00 | $3.15 | 12.70 |
| 2024-03-31 | 43.91 | $2.91 | 15.09 |
| 2023-12-31 | 61.85 | $2.60 | 23.79 |
| 2023-09-30 | 45.99 | $2.54 | 18.11 |
| 2023-06-30 | 57.47 | $1.93 | 29.78 |
| 2023-03-31 | 37.50 | $1.77 | 21.19 |
| 2022-12-31 | 28.02 | $1.74 | 16.10 |
| 2022-09-30 | 28.10 | $1.50 | 18.73 |
| 2022-06-30 | 34.79 | $1.79 | 19.44 |
| 2022-03-31 | 35.90 | $1.62 | 22.16 |
| 2021-12-31 | 23.29 | $1.25 | 18.63 |
| 2021-09-30 | 19.01 | $0.72 | 26.40 |
| 2021-06-30 | 20.16 | $0.21 | 96.00 |
| 2021-03-31 | 18.32 | $0.05 | 366.40 |
| 2020-12-31 | 20.11 | $0.03 | 670.33 |
| 2020-09-30 | 18.75 | $0.13 | 144.23 |
| 2020-06-30 | 22.46 | $0.08 | 280.75 |
| 2020-03-31 | 14.84 | $1.04 | 14.27 |
| 2019-12-31 | 19.29 | $0.98 | 19.68 |
| 2019-09-30 | 19.83 | $1.05 | 18.89 |
| 2019-06-30 | 21.11 | $1.07 | 19.73 |
| 2019-03-31 | 20.43 | $0.05 | 408.60 |
| 2018-12-31 | 19.90 | $-0.12 | 0.00 |
| 2018-09-30 | 19.24 | $-0.14 | 0.00 |
| 2018-06-30 | 15.26 | $-0.19 | 0.00 |
| 2018-03-31 | 18.75 | $-0.09 | 0.00 |
| 2017-12-31 | 19.24 | $0.08 | 240.50 |
| 2017-09-30 | 17.87 | $-0.01 | 0.00 |
| 2017-06-30 | 17.86 | $0.07 | 255.14 |
| 2017-03-31 | 14.50 | $0.18 | 80.56 |
| 2016-12-31 | 18.42 | $0.21 | 87.71 |
| 2016-09-30 | 18.97 | $0.45 | 42.16 |
| 2016-06-30 | 16.12 | $0.30 | 53.73 |
| 2016-03-31 | 12.00 | $0.00 | 0.00 |
| 2015-12-31 | 14.23 | $-0.06 | 0.00 |
| 2015-09-30 | 11.69 | $-0.29 | 0.00 |
| 2015-06-30 | 17.58 | $-0.34 | 0.00 |
| 2015-03-31 | 14.96 | $-0.22 | 0.00 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $1.019B | $0.720B |
| Amphastar Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses primarily on developing, manufacturing, marketing, and selling generic and proprietary injectable and inhalation products. The company products include Enoxaparin Sodium Injection; Amphadase; Cortrosyn for Injection; and prefilled disposable emergency syringes for crash cart use. Amphastar Pharmaceuticals, Inc. is headquartered in Rancho Cucamonga, California. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $44.899B | 17.67 |
| BridgeBio Pharma (BBIO) | United States | $13.352B | 0.00 |
| Dr Reddy's Laboratories (RDY) | India | $9.749B | 24.85 |
| Aspen Pharmacare (APNHY) | South Africa | $4.248B | 0.00 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.409B | 20.18 |
| Bausch Health Cos (BHC) | Canada | $2.129B | 1.33 |
| Personalis (PSNL) | United States | $1.687B | 0.00 |
| Taysha Gene Therapies (TSHA) | United States | $1.652B | 0.00 |
| Assembly Biosciences (ASMB) | United States | $0.519B | 24.98 |
| Sol-Gel Technologies (SLGL) | Israel | $0.178B | 0.00 |
| Metagenomi Therapeutics (MGX) | United States | $0.043B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |